Reporting Guidelines
SCIENTIFIC REPORTING STANDARDS
Reporting Guidelines
Promoting transparency, completeness and reproducibility in pharmaceutical research.
CRJPAS encourages authors to follow internationally recognized reporting guidelines appropriate to the design and methodology of their research.
Reporting guidelines support transparent communication of research methods and findings, enabling scientific evaluation, reproducibility and evidence synthesis.
Recommended Reporting Standards
| Guideline | Applicable Study Design |
|---|---|
| CONSORT 2025 | Randomized controlled trials |
| PRISMA 2020 | Systematic reviews and meta-analyses |
| STROBE | Observational studies |
| CARE | Clinical case reports |
| ARRIVE 2.0 | Animal research |
| STARD | Diagnostic accuracy studies |
| SPIRIT 2025 | Clinical trial protocols |
| CHEERS 2022 | Health economic evaluations |
Reporting Checklists
Where a relevant reporting guideline exists, authors should prepare their manuscripts in accordance with the applicable checklist and submit the completed checklist if requested by the editorial office.
Clinical Trial Registration
Clinical trials must satisfy applicable prospective registration and research ethics requirements. Authors should disclose the clinical trial registry, registration number and relevant registration dates.
Data and Statistical Transparency
Authors should describe statistical methods, sample size considerations, primary outcomes, uncertainty measures, missing data and any relevant methodological limitations sufficiently for scientific evaluation.
Official Resources
- EQUATOR Network — Research Reporting Guidelines
- ICMJE Recommendations
- CONSORT and SPIRIT
- PRISMA Statement
Reporting guidelines improve the completeness of scientific reporting but do not replace appropriate study design, ethical approval, methodological quality or independent peer review.